Phase 3 Data on Brilaroxazine for Schizophrenia with Larry Ereshefsky, PharmD
In an interview with HCPLive, Larry Ereshefsky, PharmD discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
Source: hcplive.com